The Grizzly, September 4, 2003

A Space to Call Your Own • Pay for Print Solution • Bumpy Ride • Spotlight on Politics: The California Recall • Feeling Disconnected: Internet and Virus Woes • A Plan for Every Future: Career Services Fall 2003 • Opinions: Campus Rooms: Is Space Running Out?; Network Gripes Getting you Down? Elections in California: Business as Usual or Free for All? • Activities, Activities, Activities • Calling all Thespians! • Ursinus in 1893: What was it Like? • New Arts Center • Local Heritage Day Celebration • Bears Versatility Makes the Season Look Promising • UC Field Hockey Team: Ready to Rumble • Promising Season Abound for the Men and Women\u27s Soccer Teams • Ursinus Cross Country Kicks-off • Ursinus Volleyball Team Off to Rough Start • X-Country Team Scoreshttps://digitalcommons.ursinus.edu/grizzlynews/1539/thumbnail.jp

The Grizzly, October 16, 2003

Feeling Drained for a Good Cause: Omega Chi Blood Drive • CAB Laugh-off Left Students Rolling in the Aisles • UC in the City Program Announces Easier Access to Philly • Political Pagemakers: Democratic Candidates for President • California Recall Circus has its Star • Club Spotlight: Forensics • Opinions: UC in the City: An Attempt to Fight the Boredom; California Recall Election Democracy at its Best; Video Games as Government Training Tools; Flu Season is Near; Legal BAC Should Still be Lower; Myrin Library: Use It • On the Verge Review: Memorable • Believe it or Not: A Tree in the End Zone • Meet Dr. Zwerling • Job Fair Success • 2003 Homecoming Court • Women\u27s Rugby: A Tough and Spirited Group of Ladies • Field Hockey Team Remains Undefeated in Conference • Men\u27s Soccer Continues to Face Tough Losses • Volleyball 2-3 in Conference Play • Sue Hadfield Named Head Swimming Coachhttps://digitalcommons.ursinus.edu/grizzlynews/1545/thumbnail.jp

The Grizzly, November 6, 2003

Ursinus to Take its Place in the Future • Sticks and Stones: Hate Speech on Campus • Students Bug Out after Insect Invasion • Election Day: Mud Slinging and Politics • Look Back at October: Breast Cancer Month • Opinions: OCD: Harmless Passions or Medical Disorder?; Struggling with OCD, the Disorder; Finding Ways to Cope with the Parting of a Pet; Rush Limbaugh: Another Conservative Hypocrite; Pot Smoking Equals Lower Stamina?; Registering Online: An Extreme Inconvenience • Poet Comes to U.C. • Careers in Criminology and Investigation • Meet Dr. Kozusko: The New Shakespeare Professor • Perceptions of Greeks in the Media, UC • Greek Life Fifty Years Ago • Rushing: Is it for You? • Despite Loss, UC Football Team Remains Hopeful • UC XC Competes in Centennial Conference Championship • UC XC Holds 18th Annual Bear Pack Run 5K • Athletic Profile: Katie Dougherty • Women\u27s Rugby Team Makes History • UC Soccer Updateshttps://digitalcommons.ursinus.edu/grizzlynews/1547/thumbnail.jp

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570